Just reported
Q3 2026 results
From ANI Pharmaceuticals, Inc.'s results release of November 5, 2026; its quarterly report has since been filed.
Revenue
Actual
$290.8M
+28% y/y ↑
+9.3% q/q ↑
EPS, GAAP
Actual
$1.51
+34% y/y ↑
+44% q/q ↑
Operating income, GAAP
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|
| Total Revenue | $290.8M | $227.8M | +27.64% |
| Profit | $35.1M | $26.6M | +32.05% |
| Profit per share | $1.51 | $1.13 | +33.63% |
| Free Cash Flow | $70.3M | $38M | +85.19% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
NewThe latest call
FetchingANI Pharmaceuticals, Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
What management said
“In the third quarter, ANI delivered strong financial results, while advancing our transformation into a leading Rare Disease company,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
How the share price reacted
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Close before
$71.65
Nov 4, 2026
Close after
$67.41
Nov 6, 2026
Move
-5.92%
1.3M shares traded, against a normal 338.93K
What ANI Pharmaceuticals, Inc. does
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from ANI Pharmaceuticals, Inc.’s Item 2.02 8-K filed November 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
